Polymedix commences Phase 1B study of novel anticoagulant reversing agent

PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents a new class of drug, which PolyMedix calls a heptagonist, and is believed to be the only reversing agent for heparin and the Low Molecular Weight Heparins (LMWH) in clinical development.

The second clinical trial is being conducted in healthy volunteers, and will involve first administering heparin to healthy subjects, and then afterwards administering a single dose of PMX-60056. This study is intended primarily to assess the safety of using PMX-60056 in heparinized subjects, and will also measure the ability of PMX-60056 to neutralize heparin and normalize blood clotting time. This study is utilizing a crossover double-blind design, and is planned to be conducted in a total of six subjects. Results are expected by the end of 2009. Following this clinical trial, significant additional clinical studies and regulatory submissions will be required to obtain regulatory approval from the FDA and other regulatory bodies before PMX-60056 could be commercially sold.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI outperforms doctors in diagnostics but falls short as a clinical assistant